CN115160295A - 作为激酶抑制剂的酰胺化合物 - Google Patents
作为激酶抑制剂的酰胺化合物 Download PDFInfo
- Publication number
- CN115160295A CN115160295A CN202210797866.4A CN202210797866A CN115160295A CN 115160295 A CN115160295 A CN 115160295A CN 202210797866 A CN202210797866 A CN 202210797866A CN 115160295 A CN115160295 A CN 115160295A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- nhc
- cycloalkyl
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Amide compounds Chemical class 0.000 title claims abstract description 77
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 164
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 87
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 57
- 229910052736 halogen Inorganic materials 0.000 claims description 54
- 150000002367 halogens Chemical class 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 36
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 35
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N N-ethyl-N-methylamine Natural products CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 64
- 201000010099 disease Diseases 0.000 abstract description 52
- 230000001613 neoplastic effect Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 40
- 239000000203 mixture Substances 0.000 description 32
- 239000011435 rock Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 20
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 18
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 125000004076 pyridyl group Chemical group 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 description 15
- 102000001253 Protein Kinase Human genes 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 15
- 108060006633 protein kinase Proteins 0.000 description 15
- 108010041788 rho-Associated Kinases Proteins 0.000 description 15
- 102000000568 rho-Associated Kinases Human genes 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 13
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 13
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 13
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 13
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 13
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 13
- 230000002062 proliferating effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 208000032839 leukemia Diseases 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000014767 Myeloproliferative disease Diseases 0.000 description 8
- 208000012902 Nervous system disease Diseases 0.000 description 8
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 208000030159 metabolic disease Diseases 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 208000014951 hematologic disease Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 101150111584 RHOA gene Proteins 0.000 description 6
- 206010038389 Renal cancer Diseases 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 201000010982 kidney cancer Diseases 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000003570 cell viability assay Methods 0.000 description 5
- 208000016097 disease of metabolism Diseases 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010014950 Eosinophilia Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 4
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 4
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 4
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000003376 axonal effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 3
- DZLGZIGLHCRIMF-UHFFFAOYSA-N 4-pyridin-4-ylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=NC=C1 DZLGZIGLHCRIMF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 101001000061 Homo sapiens Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000016349 Myosin Light Chains Human genes 0.000 description 3
- 108010067385 Myosin Light Chains Proteins 0.000 description 3
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 3
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 3
- 206010061934 Salivary gland cancer Diseases 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 125000002785 azepinyl group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002074 deregulated effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- POTBKLVBOJZRNG-UHFFFAOYSA-N 1-hydroxy-2h-naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)CC=CC2=C1 POTBKLVBOJZRNG-UHFFFAOYSA-N 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 2
- JNZYADHPGVZMQK-UHFFFAOYSA-N 3-(aminomethyl)phenol Chemical compound NCC1=CC=CC(O)=C1 JNZYADHPGVZMQK-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- 108010089704 Lim Kinases Proteins 0.000 description 2
- 102000008020 Lim Kinases Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WGUXTQDCAZNJIF-UHFFFAOYSA-N 1-methyl-3,5-bis(trifluoromethyl)benzene Chemical compound CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGUXTQDCAZNJIF-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- IWQRJKGYECVOAA-UHFFFAOYSA-N 3-hexoxycarbonylbenzoic acid Chemical compound CCCCCCOC(=O)C1=CC=CC(C(O)=O)=C1 IWQRJKGYECVOAA-UHFFFAOYSA-N 0.000 description 1
- OCISOSJGBCQHHN-UHFFFAOYSA-N 3-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC(O)=CC2=C1 OCISOSJGBCQHHN-UHFFFAOYSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 1
- VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
- RWSWNQOCJVPCMF-UHFFFAOYSA-N 5-methyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-amine Chemical compound C1N(C)CCN2N=C(N)C=C21 RWSWNQOCJVPCMF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100023818 ADP-ribosylation factor 3 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 102000054300 EC 2.7.11.- Human genes 0.000 description 1
- 108700035490 EC 2.7.11.- Proteins 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101150072536 Flt3 gene Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 102100032535 L-seryl-tRNA(Sec) kinase Human genes 0.000 description 1
- 101710088843 L-seryl-tRNA(Sec) kinase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 102100027869 Moesin Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010035015 Pigmentary glaucoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DNVLZPNNMXMZOL-UHFFFAOYSA-N [N-]=[N+]=NN(C(=N)N)N(OC#N)C(=O)N(N=O)[N+]([O-])=O Chemical compound [N-]=[N+]=NN(C(=N)N)N(OC#N)C(=O)N(N=O)[N+]([O-])=O DNVLZPNNMXMZOL-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 229950003153 amsonate Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 108010025267 calcium-dependent protein kinase Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940053326 magnesium salt Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- OWBKDJSKHXGOJY-UHFFFAOYSA-N methyl 3-(aminomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CN)=C1 OWBKDJSKHXGOJY-UHFFFAOYSA-N 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- MYMDOKBFMTVEGE-UHFFFAOYSA-N methylsulfamic acid Chemical compound CNS(O)(=O)=O MYMDOKBFMTVEGE-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108010071525 moesin Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 201000011303 renal artery atheroma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- FYGUBWKMMCWIKB-UHFFFAOYSA-N spiro[2.3]hexane Chemical compound C1CC11CCC1 FYGUBWKMMCWIKB-UHFFFAOYSA-N 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- PHICBFWUYUCFKS-UHFFFAOYSA-N spiro[4.4]nonane Chemical compound C1CCCC21CCCC2 PHICBFWUYUCFKS-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
Abstract
本发明涉及作为激酶抑制剂的酰胺化合物。本发明还涉及这些化合物用于治疗多种疾病的用途,所述疾病包括自身免疫性疾病、心血管疾病、炎症、中枢神经系统疾病和肿瘤疾病。
Description
本申请是申请号为201780079730.7,申请日为2017年10月24日,发明名称为“作为激酶抑制剂的酰胺化合物”的中国专利申请的分案申请。
相关申请的交叉引用
本申请要求在2016年10月24日提交的美国临时专利申请号62/411,908的优先权,其内容通过引用整体并入本文。
技术领域
本发明涉及酰胺化合物,其组合物和含有其的药物,以及制备的方法和这些化合物、组合物和药物的用途。这些化合物可用于治疗与不适当的酪氨酸和/或丝氨酸/苏氨酸激酶活性相关的疾病,包括细胞增殖疾病(例如癌症)和神经疾病和炎性疾病。具体地,本公开涉及抑制Rho-激酶的化合物和组合物,治疗与Rho-激酶相关的疾病的方法,和合成这些化合物的方法。
背景技术
酶的一个重要的大家族为蛋白激酶家族。目前,存在大约500种不同的已知的蛋白激酶。蛋白激酶用于通过将ATP-Mg2+复合物的γ-磷酸酯转移至氨基酸侧链来催化各种蛋白质中所述氨基酸侧链的磷酸化。这些酶控制细胞内的大部分信号传导过程,从而通过蛋白质中丝氨酸、苏氨酸和酪氨酸残基的羟基的可逆磷酸化来控制细胞功能、生长、分化和破坏(细胞凋亡)。研究表明,蛋白激酶是许多细胞功能(包括信号转导、转录调节、细胞运动和细胞分裂)的关键调节因子。多种致癌基因也被证明编码蛋白激酶,提示激酶在肿瘤发生中发挥作用。这些过程受到高度调节,通常是通过复杂的相互作用通路,其中每种激酶自身受到一种或多种激酶的调节。因此,异常的或不适当的蛋白激酶活性可以导致出现与这种异常的激酶活性相关的疾病状态。由于它们的生理相关性、多样性和普遍性,蛋白激酶已经成为生物化学和医学研究中最重要且广泛研究的酶家族之一。
基于其磷酸化的氨基酸残基,蛋白激酶家族典型地被分为两个主要的亚家族:蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶。丝氨酸/苏氨酸激酶(PSTK)包括环AMP和环GMP依赖性蛋白激酶、钙和磷脂依赖性蛋白激酶、钙和钙调蛋白依赖性蛋白激酶、酪蛋白激酶、细胞分裂周期蛋白激酶等。这些激酶通常是细胞质的,或者(可能通过锚定蛋白)与细胞的颗粒部分相关。在许多病理学(如类风湿性关节炎、银屑病、败血性休克、骨质流失、许多癌症和其他增殖性疾病)中涉及或怀疑涉及异常的丝氨酸/苏氨酸蛋白激酶活性。因此,丝氨酸/苏氨酸激酶和它们所属的信号转导通路是药物设计的重要靶点。酪氨酸激酶使酪氨酸残基磷酸化。酪氨酸激酶在细胞调节中发挥同样重要的作用。这些激酶包括分子(如生长因子和激素)的多种受体,包括表皮生长因子受体、胰岛素受体、血小板源性生长因子受体等。研究表明,许多酪氨酸激酶是跨膜蛋白,它们的受体结构域位于细胞外部,激酶结构域位于内部。大量工作也正在开展以鉴定酪氨酸激酶的调节因子。
细胞利用的主要信号转导系统为RhoA信号传导通路。RhoA是一种小的GTP结合蛋白,其可以被多种细胞外刺激活化,如生长因子、激素、机械应激、渗透压变化以及高浓度的代谢物(如葡萄糖)。RhoA活化涉及GTP结合、构象改变、翻译后修饰(香叶基香叶基化(geranylgeranyllization)和法尼基化(famesylation))和其固有GTP酶活性的活化。活化的RhoA能够与多种效应子蛋白(包括ROCK)相互作用,并将信号传递到细胞质和细胞核中。
Rho相关蛋白激酶,ROCK1和ROCK2,构成一个激酶家族,其可以经由物理结合被RhoA-GTP复合物激活。活化的ROCK使许多底物磷酸化,并且在关键的细胞功能中发挥重要作用。ROCK的底物包括肌球蛋白轻链磷酸酶的肌球蛋白结合亚单元(MBS,也被称为MYPT1)、内收蛋白、膜突蛋白,肌球蛋白轻链(MLC)、LIM激酶以及转录因子FHL。这些底物的磷酸化调节蛋白质的生物活性,从而提供手段以改变细胞对外部刺激的应答。一个很好备案的例子是ROCK参与平滑肌收缩。在苯肾上腺素刺激后,血管平滑肌收缩。研究表明,苯肾上腺素刺激α-肾上腺素能受体,并导致RhoA的活化。活化的RhoA反过来刺激ROCK1的激酶活性,后者又使MBS磷酸化。这种磷酸化抑制肌球蛋白轻链磷酸酶的酶活性,并通过钙依赖性肌球蛋白轻链激酶(MLCK)增加肌球蛋白轻链自身的磷酸化,并因此增加肌球蛋白-肌动蛋白束的收缩性,导致平滑肌收缩。这种现象有时被称为钙致敏。除了平滑肌收缩以外,ROCK还被证明参与细胞功能,包括细胞凋亡、细胞迁移、转录活化、纤维化、胞质分裂、炎症和细胞增殖。此外,在神经元中,ROCK在通过髓鞘相关抑制因子如髓磷脂相关糖蛋白(MAG)抑制轴突生长中发挥关键作用。ROCK活性还介导发育中的神经元中生长锥的崩塌(collapse)。两种过程都被认为是通过ROCK诱导的底物(如LIM激酶和肌球蛋白轻链磷酸酶)的磷酸化介导的,导致神经元肌动蛋白-肌球蛋白系统的收缩性增加。已经建议将ROCK的抑制剂用于多种疾病的治疗。它们包括心血管疾病,如高血压、慢性和充血性心力衰竭、心脏肥大、再狭窄、慢性肾功能衰竭和动脉粥样硬化。此外,因为其具有肌肉松弛性质,其也适用于哮喘、男性勃起功能障碍、女性性功能障碍和膀胱过度活动综合征。已经显示ROCK抑制剂具有抗炎性质。因此,它们可以用于治疗神经炎性疾病,如中风、多发性硬化症、阿尔茨海默病、帕金森病、肌萎缩侧索硬化症和炎性疼痛,以及其他炎性疾病,如类风湿性关节炎、肠易激综合征和炎性肠病。此外,基于其神经突生长诱导作用,ROCK抑制剂可以是用于神经元再生的有用药物,诱导CNS内新的轴突生长和轴突跨病灶重新连接。因此,ROCK抑制剂可能用于CNS疾病的再生性(恢复性)治疗,如脊髓损伤、急性神经元损伤(中风、创伤性脑损伤)、帕金森病、阿尔茨海默病和其他神经变性疾病。由于ROCK抑制剂减少细胞增殖和细胞迁移,因此它们可用于治疗癌症和肿瘤转移。此外,有证据表明,ROCK抑制剂抑制病毒入侵后的细胞骨架重排,因此它们在抗病毒和抗细菌应用中也具有潜在的治疗价值。ROCK抑制剂也可以用于治疗胰岛素抵抗和糖尿病。
本发明人已经发现了新的杂环化合物,其为ROCK活性的抑制剂。这种衍生物可以用于治疗与不适当的或失调的ROCK活性相关的疾病。
发明内容
在本发明的一个方面,提供一种式(I)化合物:
其中:Z1为H、苯基、萘基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基取代;Z2为苯基、萘基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基取代;R为-C1-C6烷基,其任选地被一个或多个以下基团取代:H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;R1为H、-C1-C6烷基或-C3-C7环烷基,其中-C1-C6烷基或-C3-C7环烷基任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;X为一个键或-O(C1-C6烷基);并且R2和R3独立地为H、-C1-C6烷基或-C3-C7环烷基、芳基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基;或
其中R5为-Cl-C6烷基、-OCH2CH2-、-NR6CH2CH2-、-NC(O)CH2CH2-;R6为H、-C1-C6烷基或-C3-C7环烷基;其中R’或R”独立地为-H或-Cl-C6烷基;并且其中与N或O原子任选地连接的R’和R”可以一起形成4至8元环状结构。
在本发明的另一个方面,提供一种式(II)化合物:
其中:Z1为H、吡啶、嘧啶、吡唑、咪唑、噁唑、噻唑、吲唑或四唑,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基取代;Z2为苯基、萘基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基取代;R为-C1-C6烷基,其任选地被一个或多个以下基团取代:H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;R1为H、-C1-C6烷基或-C3-C7环烷基,其中-C1-C6烷基或-C3-C7环烷基任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;R2和R3独立地为H、-C1-C6烷基或-C3-C7环烷基、芳基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基;或
其中R5为-Cl-C6烷基、-OCH2CH2-、-NR6CH2CH2-或-NC(O)CH2CH2-;R6为H、-C1-C6烷基或-C3-C7环烷基;并且其中R’或R”独立地为-H或-Cl-C6烷基;与N或O原子任选地连接的R’和R”可以一起形成4至8元环状结构;并且R4为H、-C1-C6烷基或-C3-C7环烷基。
在本发明的另一个方面,提供一种式(III)化合物:
其中:Z1为H、吡啶、嘧啶、吡唑、咪唑、噁唑、噻唑、吲唑或四唑,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基取代;Z2为苯基、萘基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基;R1为H、-C1-C6烷基或-C3-C7环烷基,其中-C1-C6烷基或-C3-C7环烷基任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;R2和R3独立地为H、-C1-C6烷基或-C3-C7环烷基、芳基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基;或
其中R5为-Cl-C6烷基、-OCH2CH2-、-NR6CH2CH2-或-NC(O)CH2CH2-;R6为H、-C1-C6烷基或-C3-C7环烷基;其中R’或R”独立地为-H或-Cl-C6烷基、或-C3-C7环烷基;并且与N或O原子任选地连接的R’和R”可以一起形成4至8元环状结构。
在另一个实施方案中,本发明涉及式(IV)化合物:
其中:Z1为H、吡啶、嘧啶、吡唑、咪唑、噁唑、噻唑、吲唑或四唑,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基;R1为H、-C1-C6烷基或-C3-C7环烷基,其中-C1-C6烷基或-C3-C7环烷基任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;R2和R3独立地为H、-C1-C6烷基或-C3-C7环烷基、芳基或C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,其中任意-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环为未取代的,或者被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基;或
其中R5为-Cl-C6烷基、-OCH2CH2-、-NR6CH2CH2-或-NC(O)CH2CH2-;R6为H、-C1-C6烷基或-C3-C7环烷基;并且其中R’或R”独立地为-H或-Cl-C6烷基;并且与N或O原子任选地连接的R’和R”可以一起形成4至8元环状结构;和R7为H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、-C1-C6烷基或-C3-C7环烷基、芳基或C5-C10元杂环,其中-C1-C6烷基、-C3-C7环烷基、芳基或C5-C10元杂环任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代。
在一些方面,R为具有R构型的甲基。在其他方面,R为具有S构型的羟甲基。
在另一个实施方案中,本发明涉及一种化合物,其中R2和R3独立地为H、-C3-C7环烷基或-C3-C7环烷基甲基;其中-C3-C7环烷基或-C3-C7环烷基甲基任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代;条件是R2和R3不都为H。
在某些方面,R2和R3独立地为H、环己基、环戊基、环丁基、环丙基、环己基甲基、环戊基甲基、环丁基甲基或环丙基甲基;并且R2和R3独立地任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代。在一个方面,R1和/或R2为H。
在一些实施方案中,本发明涉及一种化合物,其选自
在其他的实施方案中,R2和R3独立地为H、苯基或苄基;其中苯基或苄基任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代;条件是R2和R3不都为H。
在一个方面,本发明提供一种化合物,其选自
在某些方面,Z1为吡啶,其任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基;Z2为C5-C10元杂环,其任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代;R2和R3独立地为H、苯基、苄基、-C3-C7环烷基或-C3-C7环烷基甲基;其中苯基、苄基、-C3-C7环烷基或-C3-C7环烷基甲基任选地被H、卤素、-OH、-CN、-COOR'、-OR’、-SR’、-OC(O)R'、-NHR'、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代;条件是R2和R3不都为H。在一个方面,R1和/或R2为H。在另一个方面,Z2为吡啶或吡唑。
在另一个实施方案中,本发明提供一种化合物,其选自
在另一个实施方案中,本发明涉及一种化合物,其选自:
在一些方面,本发明涉及一种药物组合物,其包含本文公开的化合物和药学上可接受的载体。
在其他方面,本发明提供一种在需要其的受试者中治疗与Rho相关蛋白激酶调节有关的疾病的方法,其包括向受试者施用有效量的本文公开的化合物。在一个实施方案中,所述化合物抑制Rho相关蛋白激酶。在某些方面,所述化合物抑制ROCK1。在其他方面,所述化合物抑制ROCK2。
在一些实施方案中,所述疾病为癌症、神经变性疾病、神经发育疾病、炎症或自身免疫性疾病、感染、代谢性疾病、血液疾病、心血管疾病或血管平滑肌功能障碍。
在一个方面,所述癌症为皮肤T细胞淋巴瘤(CTCL)、外周T细胞淋巴瘤(PTCL)、血管免疫母细胞性T细胞淋巴瘤(AITL)、多发性骨髓瘤、白血病、淋巴瘤、或肺癌、卵巢癌、乳腺癌、前列腺癌、胰腺癌、肝细胞癌、或肾癌。
在另一方面,所述神经变性疾病为阿尔茨海默病、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症或脊髓性肌萎缩症。
在另一方面,所述神经发育疾病为Rett综合征或C型尼曼氏病(Niemann-Picktype C)。
在一个实施方案中,所述炎症或自身免疫性疾病为哮喘、心血管炎症、肾炎、动脉硬化、类风湿性关节炎、脊椎炎性关节炎(spondylitis arthritis)、银屑病性关节炎(psoriatic arthritis)、银屑病、特应性皮炎、湿疹、多发性硬化症、系统性红斑狼疮、炎性肠病、克罗恩病、移植物抗宿主病、移植排异反应或纤维化疾病。
在另一个实施方案中,所述心血管疾病或血管平滑肌功能障碍为高血压、动脉粥样硬化、再狭窄、心脏肥大、高眼压、脑缺血、脑血管痉挛、或勃起功能障碍。
在其他方面,本发明提供一种治疗患有血液学恶性肿瘤疾病的受试者的方法,其包括:确定需要血液学恶性肿瘤疾病治疗的受试者;对需要这种治疗的受试者施用有效量的本文公开的化合物或其盐以治疗血液学恶性肿瘤疾病。在一些实施方案中,所述血液学恶性肿瘤疾病的特征在于FLT3受体酪氨酸激酶活性失调,并且所述恶性肿瘤疾病选自白血病、骨髓瘤、骨髓增生性疾病、骨髓增生异常综合征、霍奇金病、骨髓瘤、急性淋巴细胞白血病(ALL)、急性髓性白血病(AML)、急性早幼粒细胞白血病(APL)、慢性淋巴细胞白血病(CLL)、慢性骨髓白血病(CML)、慢性中性粒细胞白血病(CNL)、急性未分化白血病(AUL)、间变性大细胞淋巴瘤(ALCL)、幼淋巴细胞白血病(PML)、幼年型单核细胞白血病(JMML)、成人T细胞ALL、AML伴骨髓三系增生异常(AMLITMDS)、混合谱系白血病(MLL)、骨髓增生异常综合征(MDS)、骨髓增生性疾病(MPD)和多发性骨髓瘤(MM)。
在一个实施方案中,本发明提供一种如本文所公开的化合物,其用于治疗或预防与Rho相关蛋白激酶调节有关的疾病的用途。在另一个实施方案中,本发明涉及如本文所公开的化合物在制备用于治疗或预防与Rho相关蛋白激酶调节有关的疾病的药物中的用途。
具体实施方式
如本文所使用,卤素基团包括任何卤素。示例包括但不限于-F、-Cl、-Br或-I。
-C1-C6烷基包括任何直链或支链、饱和的或不饱和的、取代的或未取代的烃,其包含一至六个碳原子。-C1-C6烷基的示例包括但不限于甲基、乙基、丙基、异丙基、丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、己基、异己基、新己基、乙烯基、丙烯基、1-丁烯基、2-丁烯基、1-戊烯基、2-戊烯基、1-己烯基、2-己烯基、3-己烯基、乙炔基、戊炔基、1-丁炔基、2-丁炔基、1-戊炔基、2-戊炔基、1-己炔基、2-己炔基和3-己炔基。取代的-C1-C6烷基可以包括任何可应用的化学部分。可以被取代到任何上面所列-C1-C6烷基上的基团的示例包括但不限于以下示例:卤素、-Cl-C6烷基、-O-(Cl-C6烷基)、C3-C7环烷基、-OH、-CN、-COOR'、-OC(O)R'、-NHR'、N(R')2、-NHC(O)R'或-C(O)NHR'。上面表示为R'的基团可以为-H、任何-C1-C6烷基,或者当取代基为–N(R’)2时,两个R’可以任选地与它们连接的氮或氧原子形成3-、4-、5-、6-、7-元环系统。
芳基包括任何未取代的或取代的苯基或萘基。可以被取代到芳基上的基团的示例包括但不限于:卤素、-C1-C6烷基、-O-(C1-C6烷基)、-OH、-CN、-COOR'、-OC(O)R'、NHR'、N(R')2、-NHC(O),R'或-C(O)NEtR'。表示为R'的基团可以为-H或任何-C1-C6烷基。
C3-C7环烷基包括任何3-、4-、5-、6-或7-元取代的或未取代的非芳香族碳环。C3-C7环烷基的示例包括但不限于环丙基、环丁基、环戊基、环戊二烯基、环己基、环己烯基、环庚基、环庚烯基、1,3-环己二烯基、-1,4-环己二烯基、-1,3-环庚二烯基和-1,3,5-环庚三烯基。可以被取代到C3-C7环烷基上的基团的示例包括但不限于:卤素、-Cl-C6烷基、-O-(Cl-C6烷基)、-OH、-CN、-COOR'、-OC(O)R'、-NHR'、N(R')2、-NHC(O)R'或-C(O)NHR'。上面表示为R'的基团包括-H或任何未取代的-C1-C6烷基,其示例如上面所列。卤素基团包括任何卤素。示例包括但不限于-F、-Cl、-Br或-I。
杂环可以为任何任选取代的饱和的、不饱和的或芳香的环状部分,其中所述环状部分被至少一个选自氧(O)、硫(S)和氮(N)的杂原子断开。杂环可以为单环或多环。例如,合适的取代基包括卤素、卤代C1-6烷基、卤代C1-6烷氧基、氨基、脒基、酰氨基、叠氮基、氰基、胍基、羟基、硝基、亚硝基、脲、OS(O)2R、OS(O)2OR、S(O)2OR、S(O)0-2R、C(O)OR,其中R可以为H、C1-C6烷基、芳基或3至10元杂环、OP(O)OR1OR2、P(O)OR1OR2、SO2NR1R2、NR1SO2R2、C(R1)NR2、C(R1)NOR2,R1和R2可以独立地为H、C1-C6烷基、芳基或3至10元杂环、NR1C(O)R2、NR1C(O)OR2、NR3C(O)NR2R1、C(O)NR1R2、OC(O)NR1R2。对于这些基团,R1、R2和R3各自独立地选自H、C1-C6烷基、芳基或3至10元杂环,或者R1和R2与它们所连接的原子一起形成3至10元杂环。
杂环基的可能的取代基包括卤素(Br、Cl、I或F)、氰基、硝基、氧代、氨基、C1-4烷基(例如CH3、C2H5、异丙基)、C1-4烷氧基(例如OCH3、OC2H5)、卤代C1-4烷基(例如CF3、CHF2)、卤代C1-4烷氧基(例如OCF3、OC2F5)、COOH、COO-C1-4烷基、CO-C1-4烷基、C1-4烷基-S-(例如CH3S、C2H5S)、卤代C1-4烷基-S-(例如CF3S、C2F5S)、苄氧基和吡唑基。
杂环的示例包括但不限于氮杂环庚烯基(azepinyl)、氮丙啶基、氮杂环丁烯基(azetyl)、氮杂环丁烷基、二氮杂卓基、二硫杂二嗪基(dithiadiazinyl)、二氧杂氮杂卓基(dioxazepinyl)、二氧戊环基、二噻唑基、呋喃基、异噁唑基、异噻唑基、咪唑基、吗啉基、吗啉代、氧杂环丁烷基、噁二唑基、环氧乙烷基、噁嗪基、噁唑基、哌嗪基、吡嗪基、哒嗪基、嘧啶基、哌啶基(piperidyl)、哌啶基(piperidino)、吡啶基、吡喃基、吡唑基、吡咯基、吡咯烷基、噻三唑基、四唑基、噻二唑基、三唑基、噻唑基、噻吩基、四嗪基、噻二嗪基、三嗪基、噻嗪基、硫代吡喃基、呋喃并异噁唑基、咪唑并噻唑基、噻吩并异噻唑基、噻吩并噻唑基、咪唑并吡唑基、环戊基吡唑基、吡咯并吡咯基、噻吩并噻吩基、噻二唑并嘧啶基、噻唑并噻嗪基、噻唑并嘧啶基、噻唑并吡啶基、噁唑并嘧啶基、噁唑并吡啶基、苯并噁唑基、苯并异噻唑基、苯并噻唑基、咪唑并吡嗪基、嘌呤基、吡唑并嘧啶基、咪唑并吡啶基、苯并咪唑基、吲唑基、苯并氧杂噻吩基(benzoxathiolyl)、苯并二氧杂环戊烯基、苯并二硫杂环戊烯基、吲嗪基、吲哚啉基、异吲哚啉基、呋喃并嘧啶基、呋喃并吡啶基、苯并呋喃基、异苯并呋喃基、噻吩并嘧啶基、噻吩并吡啶基、苯并噻吩基、环戊并噁嗪基、环戊并呋喃基、苯并噁嗪基、苯并噻嗪基、喹唑啉基、萘并吡啶基、喹啉基、异喹啉基、苯并吡喃基、吡啶并哒嗪基和吡啶并嘧啶基。
本发明进一步涵盖化合物可以采用的任何其他物理化学或立体化学形式。这些形式包括非对映异构体、外消旋体、分离的对映异构体、水合形式、溶剂化形式、任何已知或尚未公开的结晶或无定形形式,包括所有多晶型结晶形式。无定形形式缺乏可辨认的晶格,因此缺乏结构单元的有序排列。许多药物化合物具有无定形形式。产生这种化学形式的方法是本领域技术人员熟知的。
本发明的另一方面为式I、II或III中带有R或-CH2OH或R4的碳原子可以具有“S”或“R”构型。所有非对映异构体、外消旋体、分离的对映异构体均在本发明的范围内。
化合物的外消旋体、单个对映异构体或非对映异构体可以通过现在已知或尚未公开的任何方法通过特异性合成或拆分来制备。例如,可以通过使用光学活性酸成盐形成非对映体对,来将化合物拆分成对映异构体。将对映异构体分级结晶,并再形成游离碱。在另一个示例中,可以通过色谱法分离对映异构体。这种色谱法可以是现在已知的或尚未公开的、适用于分离对映体的任何合适的方法,如手性柱HPLC。
在本发明的一些方面,所述化合物为药学上可接受的盐的形式。药学上可接受的盐包括衍生自有机酸或无机酸的任何盐。这些盐的示例包括但不限于以下:氢溴酸、盐酸、硝酸、磷酸和硫酸的盐。有机酸加成盐包括,例如,乙酸、苯磺酸、苯甲酸、樟脑磺酸、柠檬酸、2-(4-氯苯氧基)-2-甲基丙酸、1,2-乙二磺酸、乙磺酸、乙二胺四乙酸(EDTA)、富马酸、葡庚糖酸、葡萄糖酸、谷氨酸、N-羟乙酰基阿散酸(N-glycolylarsanilic acid)、4-己基间苯二酚、马尿酸、2-(4-羟基苯甲酰基)苯甲酸、1-羟基-2-萘甲酸、3-羟基-2-萘甲酸、2-羟基乙磺酸、乳糖酸、正十二烷基硫酸、马来酸、苹果酸、扁桃酸、甲磺酸、甲基硫酸、粘酸、2-萘磺酸、双羟萘酸、泛酸、磷脂酸((4-氨基苯基)膦酸)、苦味酸、水杨酸、硬脂酸、琥珀酸、单宁酸、酒石酸、对苯二甲酸、对甲苯磺酸、10-十一碳烯酸或现在已知或尚未公开的任何其他酸的盐。应理解,这些盐可以用于治疗,条件是它们是药学上可接受的。可以通过本领域技术人员已知的方式使化合物与合适的酸反应来制备这些盐。
以下是代表本发明不同方面的示例。这些示例不应被解释为限制本公开的范围。本发明范围内的替代机理途径和类似结构对于本领域技术人员是显而易见的。
示例中的元素(elements)和行为(acts)旨在为了简化而阐明本发明,并且不一定根据任何特定的顺序或实施方案来呈现。
在本公开中使用冠词“一(a)”和“一个(an)”来指代冠词的一个或多于一个(例如,至少一个)语法对象。举例来说,“一个元素”表示一个元素或多于一个元素。
除非另有说明,在本公开中使用术语“和/或”以表示“和”或“或”。
术语“任选取代的”被理解为是指指定的化学部分(例如,烷基)可以(但不要求)与其他取代基(例如,杂原子)键合。例如,任选被取代的烷基可以为完全饱和的烷基链(例如,纯烃)。可选地,同一任选被取代的烷基可以具有不同于氢的取代基。例如,其可以在链的任何位置与卤素原子、羟基或本文所描述的任何其他取代基键合。因此,术语“任选被取代的”是指指定的化学部分具有包含其他官能团的可能,但不一定具有任何其他官能团。
术语“芳基”是指具有1至2个芳香环的环状芳香族烃基团,包括单环或双环基团,如苯基、联苯基或萘基。当含有两个芳香环(双环等)时,芳基的芳香环可以在单个点位连接(例如,联苯基),或稠合(例如,萘基)。芳基可以在任何连接点任选地被一个或多个取代基(例如1至5个取代基)取代。示例性取代基包括但不限于-H、-卤素、-0-Ci-C6烷基、-C C6烷基、-OC2-C6烯基、-OC2-C6炔基、-C2-C6烯基、-C2-C6炔基、-OH、-OP(0)(OH)2、-OC(0)Ci-C6烷基、-C(0)Ci-C6烷基、-OC(0)OCi-C6烷基、-H2、-H(Ci-C6烷基)、-N(Ci-C6烷基)2、-S(0)2-Ci-C6烷基、-S(0)HCi-C6烷基和-S(0)N(Ci-C6烷基)2。取代基自身可以任选地被取代。此外,当含有两个稠合环时,本文定义的芳基可以具有与完全饱和的环稠合的不饱和的或部分饱和的环。这些芳基的示例性环系统包括茚满基、茚基、四氢萘基和四氢苯并轮烯基(tetrahydrobenzoannulenyl)。
除非另外特别定义,“杂芳基”是指具有5至24个环原子的单价单环芳香族基团或多环芳香族基团,其含有一个或多个选自N、S、P和O的环杂原子,其余环原子为C。如本文所定义的杂芳基还表示双环杂芳香族基团,其中杂原子选自N、S、P和O。芳香族基团任选独立地被一个或多个本文所描述的取代基取代。示例包括但不限于呋喃基、噻吩基、吡咯基、吡啶基、吡唑基、嘧啶基、咪唑基、异噁唑基、噁唑基、噁二唑基、吡嗪基、吲哚基、噻吩-2-基、喹啉基、苯并吡喃基、异噻唑基、噻唑基、噻二唑、吲唑、苯并咪唑基、噻吩并[3,2-b]噻吩、三唑基、三嗪基、咪唑并[1,2-b]吡唑基、呋喃并[2,3-c]吡啶基、咪唑并[1,2-a]吡啶基、吲唑基、吡咯并[2,3-c]吡啶基、吡咯并[3,2-c]吡啶基、吡唑并[3,4-c]吡啶基、噻吩并[3,2-c]吡啶基、噻吩并[2,3-c]吡啶基、噻吩并[2,3-b]吡啶基、苯并噻唑基、吲哚基、二氢吲哚基、吲哚酮基(indolinonyl)、二氢苯并噻吩基、二氢苯并呋喃基、苯并呋喃、色满基、硫代色满基、四氢喹啉基、二氢苯并噻嗪、二氢苯并环氧乙烷基(dihydrobenzoxanyl)、喹啉基、异喹啉基、1,6-萘啶基、苯并[de]异喹啉基、吡啶并[4,3-b][1,6]萘啶基、噻吩并[2,3-b]吡嗪基、喹唑啉基、四唑并[1,5-a]吡啶基、[1,2,4]三唑并[4,3-a]吡啶基、异吲哚基、吡咯并[2,3-b]吡啶基、吡咯并[3,4-b]吡啶基、吡咯并[3,2-b]吡啶基、咪唑并[5,4-b]吡啶基、吡咯并[1,2-a]嘧啶基、四氢吡咯并[1,2-a]嘧啶基、3,4-二氢-2H-l2-吡咯并[2,1-b]嘧啶、二苯并[b,d]噻吩、吡啶-2-酮、呋喃并[3,2-c]吡啶基、呋喃并[2,3-c]吡啶基、1H-吡啶并[3,4-b][1,4]噻嗪基、苯并噁唑基、苯并异噁唑基、呋喃并[2,3-b]吡啶基、苯并噻吩基、1,5-萘啶基、呋喃并[3,2-b]吡啶、[1,2,4]三唑并[1,5-a]吡啶基、苯并[1,2,3]三唑基、咪唑并[1,2-a]嘧啶基、[1,2,4]三唑并[4,3-b]哒嗪基、苯并[c][1,2,5]噻二唑基、苯并[c][1,2,5]噁二唑、1,3-二氢-2H-苯并[d]咪唑-2-酮、3,4-二氢-2H-吡唑并[1,5-b][1,2]噁嗪基、4,5,6,7-四氢吡唑并[1,5-a]吡啶基、噻唑并[5,4-d]噻唑基、咪唑并[2,1-b][1,3,4]噻二唑基、噻吩并[2,3-b]吡咯基、3H-吲哚基及其衍生物。
此外,当含有两个稠合环时,本文定义的杂芳基可以具有与完全饱和的环稠合的不饱和的或部分饱和的环。这些杂芳基的示例性环系统包括二氢吲哚基、吲哚酮基、二氢苯并噻吩基、二氢苯并呋喃、色满基、硫代色满基、四氢喹啉基、二氢苯并噻嗪、3,4-二氢-1H-异喹啉基、2,3-二氢苯并呋喃、二氢吲哚基、吲哚基和二氢苯并环氧乙烷基。
“烷基”是指直链或支链饱和烃。Ci-C6烷基含有1至6个碳原子。Ci-C6烷基的示例包括但不限于甲基、乙基、丙基、丁基、戊基、异丙基、异丁基、仲丁基和叔丁基、异戊基和新戊基。
术语“烯基”是指含有碳-碳双键的脂肪族烃基团,其可以是直链的或支链的,在链中具有约2至约6个碳原子。烯基可以在链中具有2至约4个碳原子。“支链的”是指一个或多个低级烷基(如甲基、乙基或丙基)与直链烯基链连接。示例性的烯基包括乙烯基、丙烯基、正丁烯基和异丁烯基。C2-C6烯基为含有2至6个碳原子的烯基。
术语“炔基”是指含有碳-碳三键的脂肪族烃基团,其可以是直链的或支链的,在链中具有约2至约6个碳原子。炔基可以在链中具有2至约4个碳原子。“支链的”是指一个或多个低级烷基(如甲基、乙基或丙基)与直链炔基链连接。示例性的炔基包括乙炔基、丙炔基、正丁炔基、2-丁炔基、3-甲基丁炔基和正戊炔基。C2-C6炔基为含有2至6个碳原子的炔基。
术语“环烷基”是指含有3-18个碳原子的单环或多环饱和碳环。环烷基的示例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基、降冰片烷基(norboranyl)、降冰片烯基(norborenyl)、双环[2.2.2]辛基或双环[2.2.2]辛烯基。C3-C8环烷基为含有3至8个碳原子的环烷基。环烷基可以为稠合的(例如十氢化萘)或桥接的(例如降冰片烷)。
术语“环烯基”是指含有3-18个碳原子的单环、非芳香族不饱和碳环。环烯基的示例包括但不限于环戊烯基、环己烯基、环庚烯基、环辛烯基和降冰片烯基。C3-C8环烯基为含有3至8个碳原子的环烯基。
术语“杂环基”或“杂环烷基”或“杂环”是指含有碳和选自氧、氮或硫的杂原子的单环或多环3至24元环,其中环碳或杂原子之间没有共享离域的π电子(芳香性)。杂环基环包括但不限于氧杂环丁烷基、氮杂环丁烷基、四氢呋喃基、吡咯烷基、噁唑啉基、噁唑烷基、噻唑啉基、噻唑烷基、吡喃基、硫代吡喃基、四氢吡喃基、二噁烷基、哌啶基、吗啉基、硫代吗啉基、硫代吗啉基S-氧化物、硫代吗啉基S-二氧化物、哌嗪基、氮杂卓基(azepinyl)、氧杂卓基(oxepinyl)、二氮杂卓基、托品烷基(tropanyl)和高托品烷基(homotropanyl)。杂环基或杂环烷基环也可以为稠合的或桥接的,例如可以为双环。
如本文所使用,术语“卤代(halo)”或“卤素(halogen)”表示氟、氯、溴或碘。
术语“羰基”是指由与氧原子双键连接的碳原子组成的官能团。其在本文中可以简称为“氧代”、C(O)或C=0。
“螺环”或“螺环的”是指碳原子双环系统,其中两个环通过单个原子连接。环的尺寸和性质可以不同,或者尺寸和性质相同。示例包括螺戊烷、螺己烷、螺庚烷、螺辛烷、螺壬烷或螺癸烷。螺环中的一个或两个环可以与另一个碳环、杂环、芳环或杂芳环稠合。螺环中的一个或多个碳原子可以被杂原子(例如,O、N、S或P)取代。C3-C12螺环为含有5至12个碳原子的螺环。一个或多个碳原子可以被杂原子取代。
术语“螺环杂环”或“螺杂环”应理解为是指螺环,其中至少一个环为杂环(例如,至少一个环为呋喃基、吗啉基或哌啶基)。
本公开还包括药物组合物,其包含有效量的本公开的化合物和药学上可接受的载体。代表性的“药学上可接受的盐”包括例如水溶性和水不溶性盐,如乙酸盐、氨芪磺酸盐(amsonate)(4,4-二氨基芪-2,2-二磺酸盐)、苯磺酸盐、苯甲酸盐、碳酸氢盐、硫酸氢盐、酒石酸氢盐、硼酸盐、溴化物、丁酸盐、钙盐、乙二胺四乙酸钙、樟脑磺酸盐(camsylate)、碳酸盐、氯化物、柠檬酸盐、克拉维酸盐、二盐酸盐、乙二胺四乙酸盐、乙二磺酸盐(edisylate)、依托酸盐(estolate)、乙磺酸盐(esylate)、富马酸盐、葡庚糖酸盐、葡萄糖酸盐、谷氨酸盐、乙二醇对氨基苯胂酸盐(glycollylarsanilate)、六氟磷酸盐、己基间苯二酚盐、肼胺(hydrabamine)、氢溴酸盐、盐酸盐、羟基萘甲酸盐、碘化物、羟乙基磺酸盐、乳酸盐、乳糖酸盐、月桂酸盐、镁盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基溴化物、甲基硝酸盐、甲基硫酸盐、粘酸盐、萘磺酸盐、硝酸盐、N-甲基葡糖胺铵盐、3-羟基-2-萘甲酸盐、油酸盐、草酸盐、棕榈酸盐、双羟萘酸盐(1,1-亚甲基-双-2-羟基-3-萘甲酸盐,einbonate)、泛酸盐、磷酸盐/二磷酸盐、苦味酸盐、聚半乳糖醛酸盐、丙酸盐、对甲苯磺酸盐、水杨酸盐、硬脂酸盐、次乙酸盐、琥珀酸盐、硫酸盐、次水杨酸盐、琥珀酸盐、丹宁酸盐、酒石酸盐、茶氯酸盐(teoclate)、甲苯磺酸盐、三乙碘化物和戊酸盐。
术语“立体异构体”是指化合物的组,其具有相同数量和类型的原子,并且在那些原子之间具有相同键连接性,但在三维结构上不同。术语“立体异构体”是指该化合物组的任何成员。
术语“非对映异构体”是指立体异构体的组,其不能通过围绕单键的旋转而重叠。例如,顺式和反式双键、双环系统中的环内和环外取代,以及含有多个立体中心具有不同相对构型的化合物被认为是非对映异构体。术语“非对映异构体”是指该化合物组的任何成员。在所呈现的一些示例中,合成路线可以产生单一非对映异构体或非对映异构体的混合物。在一些情况下,这些非对映异构体被分离,在其他情况下,使用波状键来指示构型可变的结构元素。
术语“对映异构体”是指一对立体异构体,它们彼此为不可重叠的镜像。术语“对映异构体”是指这对立体异构体中的单个成员。术语“外消旋”是指一对对映体的1:1混合物。
术语“互变异构体”是指化合物的组,其具有相同数量和类型的原子,但键连接性不同并且彼此处于平衡状态。“互变异构体”为该化合物组中的单个成员。典型地,绘制单个互变异构体,但应理解,该单个结构意在表示所有可能存在的互变异构体。示例包括烯醇-酮互变异构。当绘制酮时,应理解烯醇和酮形式都是本公开的一部分。
当涉及使用化合物时,“有效量”为对于治疗或预防如本文所描述的受试者中疾病的有效的量。
如本公开所使用的术语“载体”涵盖载体、赋形剂和稀释剂,是指材料、组分或载体(vehicle),如液体或固体填充剂、稀释剂、赋形剂、溶剂或包封材料,其涉及将药剂从受试者身体的一个器官或一部分携带或运输到身体的另一个器官或一部分。
对于受试者,术语“治疗”是指改善受试者的疾病的至少一种症状。治疗包括治愈、改善或至少部分地减轻疾病。
除非另有说明,在本公开中使用术语“疾病(disorder)”以表示术语疾病(disease)、病症(condition)或疾患(illness),并且可与其互换使用。
如本公开中所使用的术语“施用(administer)”、“施用(administering)”或“施用(administration)”是指将本公开的化合物或本公开的化合物的药学上可接受的盐或组合物直接施用于受试者,或者将化合物或化合物的药学上可接受的盐或组合物的前药衍生物或类似物施用于受试者,所述前药衍生物或类似物可以在受试者体内形成等量的活性化合物。
如本公开中所使用的术语“前药”是指一种化合物,其可以通过代谢方式(例如通过水解)在体内转化为本公开的化合物。此外,如本文所使用,前药是一种药物,其在体内无活性,但典型地在胃肠道吸收期间或吸收后在体内转化为活性化合物。前药可以通过化学或生物学方式(例如,使用酶)在体内转化为活性化合物。
术语“溶剂化物”是指由溶质和溶剂形成的可变化学计量的复合物。出于本公开的目的,这种溶剂将不干扰溶质的生物活性。合适的溶剂的示例包括但不限于水、MeOH、EtOH和AcOH。其中水为溶剂分子的溶剂化物典型地被称为水合物。水合物包括含有化学计量的水的组分,以及含有可变量的水的组分。
术语“异构体”是指具有相同组成和分子量但物理和/或化学性质不同的化合物。结构差异可以为构造上的(几何异构体)或旋转偏振光平面的能力上的(立体异构体)。对于立体异构体,本公开的化合物可以具有一个或多个不对称碳原子,并且可以作为外消旋体、外消旋混合物和单独的对映异构体或非对映异构体而存在。
“患者”或“受试者”为哺乳动物,例如人、小鼠、大鼠、豚鼠、狗、猫、马、牛、猪或非人灵长类动物,如猴子、黑猩猩、狒狒或恒河猴。
如本文所使用,术语“FLT3突变的增殖性疾病”、“与FLT3有关的疾病”、“与FLT3受体有关的疾病”、“与FLT3受体酪氨酸激酶有关的疾病”、“失调的FLT3受体酪氨酸激酶疾病”或“FLT3驱动的细胞增殖性疾病”包括与FLT3活性相关或涉及FLT3活性的疾病,例如,导致FLT3的组成型活化的突变。“FLT3突变的增殖性疾病”的示例包括由于FLT3的突变导致的FLT3过度刺激引起的疾病,或者由于FLT3中异常大量的突变导致的异常高的FLT3活性引起的疾病。已知FLT3的过度活性涉及许多疾病的发病机理,包括下面列出的细胞增殖性疾病、肿瘤性疾病和癌症。用本发明治疗的增殖性疾病的非限制性示例包括白血病、骨髓瘤、骨髓增生性疾病、骨髓增生异常综合征、特发性嗜酸性粒细胞增多综合症(HES)、膀胱癌、乳腺癌、宫颈癌、CNS癌、结肠癌、食道癌、头颈癌、肝癌、肺癌、鼻咽癌、神经内分泌癌、卵巢癌、胰腺癌、前列腺癌、肾癌、唾液腺癌、小细胞肺癌、皮肤癌、胃癌、睾丸癌、甲状腺癌、子宫癌和恶性血液病。
如本文所使用,术语“增殖性疾病”和“细胞增殖性疾病”是指在多细胞生物体中一种或多种细胞子集合(subset)的过度细胞增殖,其导致对多细胞生物体的伤害(即,不适或预期寿命降低)。细胞增殖性疾病可发生在不同类型的动物和人类中。如本文所使用,“细胞增殖性疾病”包括肿瘤性疾病。
如本文所使用,术语“肿瘤性疾病”是指由异常或不受控制的细胞生长引起的肿瘤。肿瘤性疾病的示例包括但不限于以下疾病,例如:骨髓增生性疾病,如血小板减少症、原发性血小板增多症(ET)、原因不明的髓样化生、骨髓纤维化(MF)、髓样化生性骨髓纤维化(myelofibrosis with myeloid metaplasia,MMM)、慢性特发性骨髓纤维化(UIMF)和真性红细胞增多症(PV)、血球减少症和恶变前骨髓增生异常综合征;癌症,如胶质瘤、肺癌、乳腺癌、结肠直肠癌、前列腺癌、胃癌、食道癌、结肠癌、胰腺癌、卵巢癌,和血液学恶性肿瘤,包括骨髓增生异常、多发性骨髓瘤、白血病和淋巴瘤。血液学恶性肿瘤的示例包括例如白血病、淋巴瘤、霍奇金病和骨髓瘤。以及,急性淋巴细胞白血病(ALL)、急性髓性白血病(AML)、急性早幼粒细胞白血病(APL)、慢性淋巴细胞白血病(CLL)、慢性骨髓白血病(CML)、慢性中性粒细胞白血病(CNL)、急性未分化白血病(AUL)、间变性大细胞淋巴瘤(ALCL)、幼淋巴细胞白血病(PML)、幼年型单核细胞白血病(JMML)、成人T细胞ALL、AML伴骨髓三系增生异常(AMLITMDS)、混合谱系白血病(MLL)、骨髓增生异常综合征(MDS)、骨髓增生性疾病(MPD)和多发性骨髓瘤(MM)。在某些实施方案中,本发明涉及足以治疗肿瘤性疾病的量的本文公开的化合物或其药学上可接受的盐的用途。
本发明的另一个实施方案包括一种用于特异性抑制失调的受体酪氨酸激酶的方法,其包括:获得患者样品并确定何种受体酪氨酸激酶是失调的;向需要这种治疗的哺乳动物施用有效量的本文公开的化合物或其盐,其中失调的受体酪氨酸激酶为FLT3受体酪氨酸激酶。在一个方面,本文公开的化合物或其盐的有效量为可以减少患者循环外周血胚细胞(blast)数的量。在另一方面,本公开的本文公开的化合物或其盐的有效量为可以减少患者骨髓胚细胞数的量。在另一方面,增殖性疾病选自白血病、骨髓瘤、骨髓增生性疾病、骨髓增生异常综合征、特发性嗜酸性粒细胞增多症(HES)、膀胱癌、乳腺癌、宫颈癌、CNS癌、结肠癌、食道癌、头颈癌、肝癌、肺癌、鼻咽癌、神经内分泌癌、卵巢癌、胰腺癌、前列腺癌、肾癌、唾液腺癌、小细胞肺癌、皮肤癌、胃癌、睾丸癌、甲状腺癌、子宫癌和恶性血液病中的至少一种。
在本公开的另一个实施方案中,本公开的化合物为对映异构体。在一些实施方案中,所述化合物为(S)-对映异构体。在其他实施方案中,所述化合物为(R)-对映异构体。在一些实施方案中,(R)-或(S)-对映异构体构型可以指定给每个分子。在其他实施方案中,(R)-或(S)-对映异构体构型可以不指定给分子,尽管进行了分子的对映异构体纯化或分离。在其他实施方案中,本公开的化合物可以为(+)或(-)对映异构体。
应理解,所有异构形式都包括在本公开内,包括其混合物。如果化合物含有双键,则取代基可以为E或Z构型或者顺式或反式构型。如果化合物含有二取代的环烷基,则环烷基取代基可以具有顺式或反式构型。所有互变异构形式也包括在内。在一些实施方案中,可以将顺式或反式构型指定给每个分子。在其他实施方案中,顺式或反式构型可以不指定给分子,尽管进行了非对映异构体的化学纯化或分离。
表1.激酶抑制剂化合物的非限制性示例。除非另有说明,具有手性中心的示例化合物代表相应的R和S对映异构体的外消旋混合物,并且所有外消旋体和分离的对映异构体都在本发明的范围内。
其他的非限制性示例为:
本发明化合物显示出改进的ROCK酶抑制活性,癌细胞生长和活力的抑制,和FLT3-ITD突变体选择性。此外,所述化合物显示出优异的药代动力学性质。作为参考,分析了两种先前表征过的化合物(即表2中的化合物A和B)。此外,本文公开的化合物普遍表现出比临床ROCK抑制剂Ripasudil更强的ROCK抑制,所述Ripasudil具有相对弱的活性(ROCK1 IC50=51nM和ROCK2 IC50=19nM)。
本公开的化合物可以通过多种方法制备,包括标准化学方法。在下面给出的方案中描述了合适的合成路线。
可以通过有机合成领域中已知的方法制备化合物,所述方法部分地通过以下合成方案和示例阐述。在下面描述的方案中,应理解在根据一般原理或化学认为必要时,采用敏感性基团或反应性基团的保护基。根据有机合成的标准方法操纵保护基(T.W.Greene和P.G.M.Wuts,"Protective Groups in Organic Synthesis",第三版,Wiley,纽约1999)。使用对本领域技术人员显而易见的方法,在化合物合成的方便阶段去除这些基团。选择过程以及反应条件和它们的实施顺序应当与式I化合物的制备相一致。
本领域技术人员将确认式I化合物中是否存在立体中心。因此,本公开还包括可能的立体异构体(除非在合成中指定),并且不仅包括外消旋化合物,还包括单独的对映异构体和/或非对映异构体。当期望化合物作为单个对映异构体或非对映异构体时,可以通过立体选择合成或通过拆分终产物或任何方便的中间体来获得所述化合物。可以通过本领域已知的任何合适方法影响终产物、中间体或起始材料的拆分。参见,例如,E.L.Eliel、S.H.Wilen和L.N.Mander的"Stereochemistry of Organic Compounds"(Wiley-lnterscience,1994)。
本文所描述的化合物可以由市售起始材料制备,或者使用已知的有机、无机和/或酶促方法合成。
本公开的另一个方面涉及一种在需要其的受试者中治疗与Rho-激酶(例如ROCK-1、ROCK2)的调节相关的疾病的方法。所述方法涉及向需要治疗与Rho-激酶(例如ROCK-1、ROCK2)的调节相关的疾病或病症的患者施用有效量的式I化合物。在一个实施方案中,所述疾病可以是但不限于癌症、神经变性疾病、神经发育疾病、炎症或自身免疫疾病、感染、代谢性疾病、血液疾病或心血管疾病。
本公开的另一个方面涉及一种抑制Rho-激酶(例如ROCK-1、ROCK2)的方法。所述方法涉及向需要其的受试者施用有效量的公开化合物。
本公开涉及组合物,其能够调节(例如,抑制)Rho-激酶(例如ROCK-1、ROCK2)的活性。本公开还涉及这些化合物的治疗用途。
本公开化合物的一种治疗用途为治疗增殖性疾病或病症,如癌症。癌症可以被理解为患者体内的异常或不受调节的细胞生长,并且可以包括但不限于肺癌、卵巢癌、乳腺癌、前列腺癌、胰腺癌、肝细胞癌、肾癌和白血病,如急性髓性白血病和急性淋巴细胞白血病。其他的癌症类型包括T细胞淋巴瘤(例如,皮肤T细胞淋巴瘤、外周T细胞淋巴瘤、血管免疫母细胞)和多发性骨髓瘤。
本公开化合物的一种治疗用途为治疗神经疾病或病症或神经变性。神经疾病被理解为神经系统(例如,脑和脊髓)的疾病。神经疾病或神经变性疾病可以包括但不限于癫痫、注意力缺陷障碍(ADD)、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、脊髓性肌萎缩、特发性震颤、组织损伤引起的中枢神经系统创伤、氧化应激诱导的神经元或轴突变性,和多发性硬化。
本公开化合物的另一种治疗用途为治疗神经发育疾病。神经发育疾病可以包括但不限于雷特综合征(Rett syndrome)。
本公开化合物的另一种治疗用途为治疗炎性疾病或病症。炎症可以被理解为宿主对原始损伤或感染的应答。炎症的症状可以包括但不限于发红、肿胀、疼痛、发热和功能丧失。炎症可以由促炎细胞因子(如IL-1β)的上调和FOXP3转录因子的表达增加而引起。
本公开化合物的另一种治疗用途还为治疗自身免疫性疾病或病症。自身免疫性疾病被理解为其中宿主自身的免疫系统对宿主体内天然存在的组织和物质产生应答的疾病。自身免疫性疾病可以包括但不限于类风湿性关节炎、脊椎炎性关节炎、银屑病性关节炎、多发性硬化症、系统性红斑狼疮、炎性肠病、移植物抗宿主病、移植排异、纤维化疾病、克罗恩病、1型糖尿病、湿疹和银屑病。
本公开化合物的另一种治疗用途为治疗感染性疾病或病症。感染或感染性病是由外来病原体的入侵引起的。感染可以由例如细菌、真菌或病毒引起。例如,细菌感染可以由大肠杆菌(E.coli)引起。
本公开化合物的另一种治疗用途为治疗代谢性疾病或病症。代谢性疾病的特征可以为受试者储存能量的方式的异常。代谢性疾病可以包括但不限于代谢综合征、糖尿病、肥胖症、高血压和心力衰竭。
本公开化合物的另一种治疗用途为治疗血液疾病。血液疾病主要影响血液。血液疾病可以包括但不限于贫血、淋巴瘤和白血病。
本公开化合物的另一种治疗用途还为治疗心血管疾病或病症。心血管疾病影响患者的心脏和血管。示例性病症包括但不限于心血管应激、压力超负荷、慢性局部缺血、梗塞-再灌注损伤、高血压、动脉粥样硬化、外周动脉疾病和心力衰竭。
在某些方面,本发明提供一种如本文所公开的化合物,其用于治疗与Rho激酶-信号传导通路的上调有关的疾病的用途。
在其他方面,本发明涉及一种治疗受试者的自身免疫性疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在一个方面,所述自身免疫性疾病为类风湿性关节炎、多发性硬化症、系统性红斑狼疮(SLE)、银屑病、克罗恩病、特应性皮炎、湿疹或移植物抗宿主病(GVHD)。
在一些实施方案中,本发明提供一种治疗受试者的心血管疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在一个实施方案中,所述心血管疾病为高血压、动脉粥样硬化、再狭窄、心脏肥大、高眼压、脑缺血、脑血管痉挛或勃起功能障碍。
在其他实施方案中,本发明提供一种治疗受试者的炎症的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在某些方面,所述炎症为哮喘、心血管炎症、肾炎或动脉硬化。
在某些方面,本发明提供一种治疗受试者的中枢神经系统疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在一个方面,所述中枢神经系统疾病为神经元变性或脊髓损伤。在另一个方面,所述中枢神经系统疾病为亨廷顿病、帕金森病、阿尔茨海默病、肌萎缩侧索硬化症(ALS)或多发性硬化症。
本发明还提供一种治疗受试者的动脉血栓形成疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在一个实施方案中,所述动脉血栓形成疾病为血小板聚集或白细胞聚集。
在其他方面,本发明涉及一种治疗受试者的纤维化疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在一个实施方案中,所述纤维化疾病为肝纤维化、肺纤维化或肾纤维化。
本发明还涉及一种在受试者中治疗青光眼或调节眼内压的方法,其包括向受试者施用治疗有效量的本文公开的化合物。在一个方面,所述青光眼为原发性开角型青光眼、急性闭角型青光眼、色素性青光眼、先天性青光眼、正常眼压性青光眼或继发性青光眼。
在一些实施方案中,本发明涉及一种治疗受试者的肿瘤性疾病的方法,其包括:向受试者施用治疗有效量的本文公开的化合物。在某些方面,所述肿瘤性疾病为淋巴瘤、癌、白血病、肉瘤或胚细胞瘤。在其他方面,所述肿瘤性疾病为鳞状细胞癌、小细胞肺癌、垂体癌、食道癌、星形细胞瘤、软组织肉瘤、非小细胞肺癌、肺腺癌、肺鳞癌、腹膜癌、肝细胞癌、胃肠癌、胰腺癌、胶质母细胞瘤、宫颈癌、卵巢癌、肝癌、膀胱癌、肝细胞瘤(hepatoma)、乳腺癌、结肠癌、结直肠癌、子宫内膜或子宫癌、唾液腺癌、肾癌、肝癌、前列腺癌、外阴癌、甲状腺癌、肝癌(hepatic carcinoma)、脑癌、子宫内膜癌、睾丸癌、胆管癌、胆囊癌、胃癌、黑色素瘤、或头颈癌。
在其他实施方案中,本发明提供一种治疗受试者的代谢综合征、胰岛素抵抗、高胰岛素血症、2型糖尿病或葡萄糖不耐受的方法,其包括向受试者施用治疗有效量的本文公开的化合物。
在一个实施方案中,本发明涉及一种在受试者中治疗骨质疏松症或促进骨形成的方法,其包括向受试者施用治疗有效量的本文公开的化合物。
在另一个实施方案中,本发明涉及一种治疗具有血管生成组分的眼疾病的方法,其包括向受试者施用治疗有效量的本文公开的化合物和血管生成抑制剂。在某些方面,所述眼疾病为年龄相关性黄斑变性(AMD)、脉络膜新生血管形成(CNV)、糖尿病性黄斑水肿(DME),虹膜新生血管形成、葡萄膜炎,新血管性青光眼、或早产儿视网膜炎(ROP)。
本公开的另一个方面涉及本公开的化合物或其药学上可接受的盐、水合物、溶剂化物、前药、立体异构体或互变异构体,其用于治疗或预防与Rho激酶调节相关的疾病的用途。在一些实施方案中,所述疾病为癌症、神经变性疾病、神经发育疾病、炎症或自身免疫性疾病、感染、代谢性疾病、血液疾病或心血管疾病。在一些实施方案中,所述化合物抑制Rho激酶。在另一个实施方案中,所述化合物抑制ROCK-1。在另一个实施方案中,所述化合物抑制ROCK-2。
在另一个方面,本公开涉及本公开的化合物或其药学上可接受的盐、水合物、溶剂化物、前药、立体异构体或互变异构体在制备用于治疗或预防与Rho激酶调节相关的疾病的药物中的用途。在一些实施方案中,所述疾病为癌症、神经变性疾病、神经发育疾病、炎症或自身免疫性疾病、感染、代谢性疾病、血液疾病或心血管疾病。在一些实施方案中,所述化合物抑制Rho激酶。在另一个实施方案中,所述化合物抑制ROCK-1。在另一个实施方案中,所述化合物抑制ROCK-2。
在一些实施方案中,所述癌症为皮肤T细胞淋巴瘤、外周T细胞淋巴瘤、血管免疫母细胞性T细胞淋巴瘤、多发性骨髓瘤、白血病、弥漫性大B细胞淋巴瘤、肺癌、卵巢癌、乳腺癌、前列腺癌、胰腺癌、肝细胞癌或肾癌。在其他实施方案中,所述神经变性疾病为阿尔茨海默病、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症或脊髓性肌萎缩症。在其他实施方案中,所述神经发育疾病为雷特综合征和C型尼曼氏病。在其他实施方案中,所述炎症或自身免疫性疾病为类风湿性关节炎、脊椎炎性关节炎、银屑病性关节炎、银屑病、多发性硬化症、系统性红斑狼疮、炎性肠病、移植物抗宿主病、移植排异或纤维化疾病。
可以以有效量施用本公开的化合物,以在受试者中治疗或预防疾病和/或预防其发展。
可以经由用于治疗剂的任何施用方式完成本公开的化合物的施用。这些方式包括全身或局部施用,如口服、鼻腔、肠胃外、透皮、皮下、阴道、口腔、直肠或局部施用方式。
根据期望的施用方式,本公开的组合物可以为固体、半固体或液体剂型,如注射剂、片剂、栓剂、丸剂、定时释放胶囊、酏剂、酊剂、乳剂、糖浆、粉末剂、液体剂、混悬剂等,有时为单位剂量并与常规药物实践一致。同样,它们还可以以静脉内(推注和输注)、腹膜内、皮下或肌内形式施用,所有这些都使用药学领域技术人员熟知的形式。
示例性的药物组合物为片剂和明胶胶囊,其包含本公开的化合物和药学上可接受的载体,如a)稀释剂,例如纯化水,甘油三酯油,如氢化或部分氢化的植物油或其混合物,玉米油、橄榄油、向日葵油、红花油、鱼油,如EPA或DHA或它们的酯或甘油三酯或其混合物,ω-3脂肪酸或其衍生物、乳糖、右旋糖、蔗糖、甘露醇、山梨糖醇、纤维素、钠、糖精、葡萄糖和/或甘氨酸;b)润滑剂,例如二氧化硅、滑石、硬脂酸、其镁盐或钙盐、油酸钠、硬脂酸钠、硬脂酸镁、苯甲酸钠、乙酸钠、氯化钠和/或聚乙二醇;对于片剂如果需要,还有c)粘合剂,例如硅酸铝镁、淀粉糊、明胶、黄蓍胶、甲基纤维素、羧甲基纤维素钠、碳酸镁、天然糖如葡萄糖或β-乳糖、玉米甜味剂、天然的和合成的树胶如阿拉伯树胶、黄蓍胶或海藻酸钠、蜡和/或聚乙烯吡咯烷酮;d)崩解剂,例如淀粉、琼脂、甲基纤维素、膨润土、黄原胶、海藻酸或其钠盐或泡腾混合物;e)吸附剂、着色剂、调味剂和甜味剂;f)乳化剂或分散剂,如吐温80、Labrasol、HPMC、DOSS,caproyl 909、labrafac、labrafil、peceol、transcutol、capmul MCM、capmul PG-12、captex 355、gelucire、维生素E TGPS或其他可接受的乳化剂;和/或g)增强化合物吸收的试剂,如环糊精、羟丙基-环糊精、PEG400、PEG200。
可以例如通过溶解、分散等制备液体组合物(特别是可注射的)。例如,将本公开的化合物溶解于药学上可接受的溶剂(如水、盐水、葡萄糖水溶液、甘油、乙醇等)中或与药学上可接受的溶剂混合,从而形成可注射的等渗溶液或混悬液。可以使用蛋白质如白蛋白、乳糜微粒或血清蛋白质以溶解本公开的化合物。
本公开的化合物也可以被配制成栓剂,其可以由脂肪乳剂或混悬剂制备;使用聚亚烷基二醇如丙二醇作为载体。
还可以以脂质体递送系统(如小单层囊泡、大单层囊泡和多层囊泡)的形式施用本公开的化合物。脂质体可以由多种磷脂形成,所述磷脂包括胆固醇、硬脂酰胺或磷脂酰胆碱。在一些实施方案中,如美国专利号No.5,262,564中所描述,脂质组分的膜与药物的水溶液水合以形成包封药物的脂质层。
还可以通过使用单克隆抗体作为单独载体来递送本公开的化合物,本公开的化合物与所述单克隆抗体偶联。本公开的化合物还可以与作为靶向药物载体的可溶性聚合物偶联。这些聚合物可以包括但不限于聚乙烯吡咯烷酮、吡喃共聚物、聚羟丙基甲基丙烯酰胺苯酚、聚羟乙基天冬酰胺苯酚(polyhydroxyethylaspanamidephenol)或被棕榈酰残基取代的聚环氧乙烷聚赖氨酸(polyethyleneoxidepolylysine)。此外,本公开的化合物可以与一类可用于实现药物控制释放的可生物降解聚合物偶联,例如聚乳酸、聚ε-己内酯、聚羟基丁酸、聚原酸酯、聚缩醛、聚二氢吡喃、聚氰基丙烯酸酯和水凝胶的交联或两亲嵌段共聚物。在一个实施方案中,本公开的化合物不与聚合物(例如多元羧酸聚合物或聚丙烯酸酯)共价结合。
肠胃外可注射施用通常用于皮下、肌肉内或静脉内注射和输注。注射剂可以以常规形式制备,所述常规形式为液体溶液或混悬液或适于在注射前溶解在液体中的固体形式。
本公开的另一个方面涉及一种药物组合物,其包含本公开的化合物和药学上可接受的载体。所述药学上可接受的载体可以进一步包括赋形剂、稀释剂或表面活性剂。
可以分别根据常规的混合、制粒或包衣方法制备组合物,并且本发明药物组合物可以含有以重量或体积计约0.1%至约99%,约5%至约90%,或约1%至约20%的本公开的化合物。
根据多种因素选择使用本公开的化合物的给药方案,所述因素包括患者的类型、种族、年龄、体重、性别和医疗状况,待治疗的病症的严重程度,施用途径,患者的肾功能或肝功能,和所采用的具体的本公开化合物。本领域普通医师或兽医可以容易地确定和规定预防、对抗或阻止病症进展所需的药物的有效量。
当用于指定的作用时,本公开的化合物的有效剂量范围为治疗病症所需的约0.5mg至约5000mg的本公开的化合物。用于体内或体外使用的组合物可以含有约0.5、5、20、50、75、100、150、250、500、750、1000、1250、2500、3500或5000mg的本公开的化合物,或者,为剂量列表中的一个量到另一个量的范围。在一个实施方案中,所述组合物为可以刻痕的片剂的形式。
不希望受到任何特定理论的束缚,本公开的化合物可以抑制Rho激酶如ROCK-1和ROCK-2。
实施例
通过以下实施例和合成实施例进一步阐明本公开,所述实施例和合成实施例不应解释为将本发明的范围或精神限定于本文所描述的具体程序。应理解,提供实施例以阐明某些实施方案,并且因此不旨在限制本公开的范围。应进一步理解,在不脱离本公开的精神和/或所附权利要求的范围的情况下,本领域技术人员可以求解出各种其他实施方案、修改和等同物。
实施例1.化合物ID#1的合成
第1步
向4-(吡啶-4-基)苯甲酸(100mg,0.50mmol)和3-(氨基甲基)苯甲酸甲酯(99mg,0.6mmol)的DMF溶液中加入二异丙基乙胺(DIEA,0.26mL,1.5mmol)和1-[双(二甲基氨基)亚甲基]-1H-1,2,3-三唑并[4,5-b]吡啶-3-氧化物六氟磷酸盐(HATU,247mg,0.65mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到1A(141mg)。
第2步
向1A(141mg,0.41mmol)的THF溶液中加入LiOH溶液(1M,2.0mL)。将反应在室温搅拌过夜,并用HCl溶液中和。将混合物浓缩并通过C-18柱色谱法纯化,以得到1B(97mg)。
第3步
向1B(7mg,0.02mmol)和5-甲基-4,5,6,7-四氢吡唑并[1,5-a]吡嗪-2-胺(6mg,0.04mmol)的DMF溶液中加入二异丙基乙胺(DIEA,0.007mL,0.04mmol)和HATU(15mg,0.04mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到ID#1(8mg)。
实施例2.化合物ID#10的合成
第1步
向4-(吡啶-4-基)苯甲酸(50mg,0.25mmol)和3-((1S)-1-氨基-2-羟乙基)苯甲酸甲酯HCl盐(75mg,0.3mmol)的DMF溶液中加入二异丙基乙胺(DIEA,0.13mL,0.75mmol)和HATU(123mg,0.32mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到2A(68mg)。
第2步
向1A(68mg,0.17mmol)的THF溶液中加入LiOH溶液(1M,0.85mL)。将反应在室温搅拌过夜,并用HCl溶液中和。将混合物浓缩并通过C-18柱色谱法纯化,以得到2B(40mg)。
第3步
向2B(5mg,0.014mmol)和环戊胺(3mg,0.035mmol)的DMF溶液中加入二异丙基乙胺(DIEA,5μL,0.028mmol)和HATU(7mg,0.018mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到ID#10(5mg)。
实施例3.化合物ID#3的合成
第1步
向4-(吡啶-4-基)苯甲酸(50mg,0.25mmol)和3-(氨基甲基)苯酚(37mg,0.3mmol)的DMF溶液中加入二异丙基乙胺(DIEA,0.13mL,0.75mmol)和HATU(123mg,0.32mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到3A(62mg)。
第2步
向3A(62mg,0.20mmol)和氯乙酸乙酯(25mg,0.20mmol)的乙腈混合物中加入碳酸钾(33mg,0.24mmol)。将反应加热至55℃,搅拌过夜,过滤并浓缩。将残余物通过C-18柱色谱法纯化,以得到3B(55mg)。
第3步
向3B(55mg,0.14mmol)的THF溶液中加入LiOH溶液(1M,0.7mL)。将反应在室温搅拌过夜,并用HCl溶液中和。将混合物浓缩并通过C-18柱色谱法纯化,以得到3C(50mg)。
第4步
向3C(10mg,0.028mmol)和环丙胺(5mg,0.084mmol)的DMF溶液中加入HATU(13mg,0.034mmol)。将反应在室温搅拌2小时,并用水稀释。将混合物浓缩并通过C-18柱色谱法纯化,以得到ID#3(10mg)。
实施例4-ROCK1和ROCK2激酶抑制试验
以下试验方案用于测量肽底物(FAM-KKLRRTLSVA-OH,其中FAM是羧基荧光素)的磷酸化。通过毛细管电泳,肽的纯度>98%。肽被蛋白激酶ROCK1或ROCK2磷酸化。将ROCK1或ROCK2酶、底物和辅因子(ATP和Mg2+)合并在微量滴定板的孔中,并在存在或不存在抑制剂化合物的情况下在25℃孵育3小时。在孵育结束时,通过加入含有EDTA的缓冲液将反应淬灭。使用Caliper Life Sciences(Hopkinton,马萨诸塞州)的基于微流体的3000Drug Discovery System,将底物和产物通过电泳分离和定量。
试验混合物的组分为:
100mM HEPES,pH 7.5
0.1%BSA
0.01%Triton X-100
1mM DTT
10mM MgCl2
10μM原钒酸钠
10μMβ-磷酸甘油
5μM ATP(对于ROCK1)或7μM ATP(对于ROCK2)
1%DMSO(来自化合物)
1.25μM FAM-KKLRRTLSVA-OH
3nM ROCK1或2.5nM ROCK2酶
使用3000毛细管电泳仪器,将每个样品中存在的底物和产物肽通过电泳分离。当底物和产物肽分离时,观察到两个荧光峰。底物和产物峰的相对荧光强度的变化是反映酶活性的测量参数。使用HTS Well Analyzer软件(Caliper Life Sciences,Hopkinton,马萨诸塞州)分析毛细管电泳图(RDA采集文件)。将每个样品的激酶活性确定为产物总和比(PSR):P/(S+P),其中P为产物肽的峰高度,S为底物肽的峰高度。对于每种化合物,在各浓度(以3X稀释间隔隔开的12个化合物浓度)测量酶活性。将阴性对照样品(在不存在抑制剂时的0%-抑制)和阳性对照样品(在存在20mM EDTA时的100%-抑制)重复收集(assemble)四次,并用于计算每种化合物在每种浓度的%-抑制值。使用以下等式确定百分比抑制(Pinh):
Pinh=(PSR0%-PSRinh)/(PSR0%-PSR100%)*100
其中PSRinh为在存在抑制剂时的产物总和比,PSR0%为在不存在抑制剂时的平均产物总和比,PSR100%为100%-抑制对照样品中的平均产物总和比。使用XLfit 4软件(IBDS),通过4-参数S形剂量-应答模式通过拟合抑制曲线(Pinh相比于抑制剂浓度)来确定抑制剂的IC50值。
该试验可以用于测试表2中确认的每种示例性化合物的活性。预期这些化合物中的每一种都将显示抑制蛋白激酶ROCK1和/或ROCK2。
实施例5.细胞活力试验
使用在不同时间点在存在不同浓度的上面所列化合物时的细胞活力以评估细胞毒性和化合物对细胞增殖的作用。表2总结了本发明的化合物在K562或MV411细胞系中的IC50(或百分比活性)数据。
细胞活力试验-通过Promega(Madison,WI)的细胞活力试验测量细胞活力。发光细胞活力试验是一种均质方法,所述方法根据定量存在的ATP来确定培养物中存活细胞的数量,其标志着代谢活性细胞的存在。在处理后,将加入到处理孔中并在37℃温育。使用Molecular Devices Spectramax酶标仪测量发光值。
实验设计
单个试剂研究-使细胞生长至70%融合,胰蛋白酶消化,计数,并以2.5×103-5×103细胞/孔的终浓度接种于96孔平底板中(第0天)。使细胞在生长介质中孵育24小时。在第1天开始用测试试剂或标准试剂处理,并持续72小时。在第72小时时间点,去除含有介质的处理。如上所描述通过细胞活力试验定量活细胞数。使用这些研究的结果以计算每种化合物的IC50值(抑制对照的50%细胞生长的药物浓度)。
数据收集-对于单个试剂和组合研究,收集每个实验的数据,并使用以下计算将其表示为细胞生长%:
细胞生长%=(f测试/f载体)x 100
其中f测试为测试的样品的发光,f载体为药物溶解的载体的发光。使用Prism 6软件(GraphPad)使用以下等式生成剂量应答图和IC50值:
Y=(顶-底)/(1+10((logIC50-X)-斜率))
其中X为浓度的对数,Y为应答。Y从底(Bottom)开始以S形形状延伸至顶(Top)。
实施例7.ROCK1和ROCK2激酶抑制和细胞活力试验结果
通常,激酶调节许多重要的细胞活动,包括细胞生长、信号传导、代谢等。不同的激酶具有不同的功能和通路。ROCK1和ROCK2的选择性抑制避免了可能引起不期望的副作用(如毒性)的脱靶活性。
按照实施例5和6中概述的方案,用表1中的化合物测试ROCK1和ROCK2激酶抑制和癌细胞活力。如表2所示,化合物显示出对ROCK1和ROCK2激酶和癌细胞的生长的抑制。
实验还评估了化合物抑制在Flt3基因中携带突变的癌细胞生长的选择性。MV411细胞系表达Flt3的突变等位基因,具有基因的内部串联重复(ITD)。参见Quentmeier等人,“FLT3 Mutations in Acute Myeloid Leukemia Cell Lines,”Leukemia 17(1),2003,120-124。K562为一种慢性髓性白血病细胞系,其不表达FLT3蛋白。参见Grafone等人,“Monitoring of FLT3 Phosphorylation Status and Its Response to Drugs By FlowCytometry in AML Blast Cells,”Hematol Oncol.26(3),2008,159-166。通过表2中更高的K562/MV411比例来确定表现出FLT3-ITD+选择性的化合物。
在急性髓性白血病(AML)、急性淋巴细胞白血病(ALL)、慢性期慢性粒细胞白血病(CML)(CML-CP)、急变期(blast crisis)CML病例(CML-BC)、慢性淋巴性白血病(CLL)、骨髓增生异常综合征(MDS)、慢性粒单核细胞白血病(CMML)、多发性骨髓瘤(MM)病例和骨髓浸润的非霍奇金淋巴瘤(NHL)中,通过聚合酶链反应(PCR)检测到FLT3/ITD基因突变。患有ITD-FLT3+急性髓性白血病(AML)的患者预后极差。
令人惊讶地,许多化合物对MV11细胞的功效高于K562细胞,提示这些化合物可以用于有效治疗FLT3-ITD+癌症,包括ITD-FLT3+AML。
表2.ROCK1和ROCK2激酶抑制和细胞活力
*MV411为ITD-FLT3+,K562不表达ITD-FLT3。如Onish等人,“Internal TandemDuplication Mutations in FLT3 Gene Augment Chemotaxis to Cxcl12 Protein byBlocking the Down-regulation of the Rho-associated Kinase via the Cxcl12/Cxcr4Signaling Axis,”J.Biol.Chem.289(45),2014,31053–31065所报道,可以操纵Rho相关激酶用于治疗ITD-FLT3+AML。
**化合物A为阳性对照(如下所示,并且由Schirok等人,“Design and Synthesisof Potent and Selective Azaindole-Based Rho Kinase(ROCK)Inhibitors,”ChemMedChem 3,2008,1893–1904描述)。
***化合物B为另一个阳性对照(如下所示,并且由Cook等人,“RHO KINASEINHIBITORS”美国专利号8,697,911描述)。
实施例8.药代动力学活性
分别精确称量化合物,以2mg/mL的浓度在二甲基亚砜(DMSO)中制备储备溶液,并在-20℃储存。通过将储备溶液在甲醇-水50:50(v/v)中稀释为20μg/mL来制备工作储备液,用于校准曲线制备,并在4℃储存。在样品处理的同一天,使用从未处理的小鼠获得的空白血浆制备用于定量的标准品和质量控制样品(QCs)。对于每种分析物,通过工作储备液的连续稀释以0.1、0.5、1.0、10、50、100、500和1000ng/mL的浓度来制备标准品;以0.75、7.5、75和750ng/mL的中间浓度制备QCs。将血浆样品储存在-80℃直至准备分析,然后置于冰上进行解冻。根据预定义的设计,将一份(aliquot)的20μL样品,标准品或QCs转移到96孔提取板中。向每个孔中加入适当体积的含有内标(25ng/mL的维拉帕米)的甲醇-甲酸99.9-0.1,并在真空下提取样品。然后,将洗脱液转移到LCMS板中,使用用于分离和MRM检测的合适的柱进行分析。基于校准曲线计算分析物的浓度,并通过使用非隔室分析(NCA)分析药代动力学参数。报告了参数如Cmax、Tmax、半衰期、AUC(0-最终)、AUC(0-∞)、分布容积(Vss)和清除率(Cl/F)。
表3.7、10和36在小鼠中的药代动力学活性
除非另外定义,本文中的所有技术和科学术语具有与本发明所属领域的普通技术人员通常理解的含义相同的含义。出于所有目的,引用的所有出版物、专利和专利出版物通过引用整体并入本文。
应理解,公开的发明不限于所描述的特定方法学、方案和材料,因为这些可以变化。还应理解,本文使用的术语仅用于描述特定实施方案的目的,并不旨在限制本发明的范围,本发明的范围仅受所附权利要求的限制。
本领域技术人员将认识到或能够使用不超过常规的实验确定本文所描述的本发明具体实施方案的许多等同物。这些等同物旨在由权利要求所涵盖。
Claims (18)
1.一种式(I)化合物:
其中:
Z1为吡啶或吡唑,其中吡啶或吡唑任选地被卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环所取代,并且其中
所述-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基;
Z2为苯基、萘基或C5-C10元杂环,其中苯基、萘基或C5-C10元杂环任选地被卤素、-OH、-CN、-COOR’、-OR’、-OR’OR”、-O(CH2)2NR’R”、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环取代,并且其中
所述-Cl-C6烷基、芳基、-C3-C7环烷基或3至10元杂环任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基或-C3-C7环烷基;
R1为H、-C1-C6烷基或-C3-C7环烷基,其中所述-C1-C6烷基或-C3-C7环烷基任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”或-S(O)2R’;
R为甲基或羟甲基;
X不存在;
所述-C1-C6烷基、-C3-C7环烷基、芳基、C5-C10元杂环任选地被卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至11元杂环取代,其中
所述-Cl-C6烷基、芳基、-C3-C7环烷基或3至11元杂环任选地被一个或多个以下基团取代:卤素、-OH、-CN、-COOR’、-CH2NR’R”、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR'R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基,并且其中
R5为-Cl-C6亚烷基、-OCH2CH2-、-NR6CH2CH2-、-NC(O)CH2CH2-;R6为H、-C1-C6烷基或-C3-C7环烷基;和
R’或R”独立地为-H或-Cl-C6烷基,或者R’和R”与它们所连接的N一起形成4至8元环状结构。
3.根据权利要求1所述的化合物,其中Z2为苯基、吡啶或吡唑,其任选地被卤素、-OR’、-Cl-C6烷基、-OR’OR”、-O(CH2)2NR’R”所取代,其中所述-Cl-C6烷基任选地被一个或多个-OR’或NR’R”取代,其中R’或R”独立地为-H、甲基或乙基。
5.根据权利要求1所述的化合物,其中R1为H、未取代的甲基、甲氧基乙基或二甲氨基乙基。
6.根据权利要求5所述的化合物,其中R1为H。
7.根据权利要求1所述的化合物,其中R为甲基或羟甲基。
8.根据权利要求7所述的化合物,其中R为具有S构型的羟甲基或具有R构型的甲基。
9.根据权利要求1所述的化合物,其中R2为H。
10.根据权利要求9所述的化合物,其中R3为-C3-C7环烷基或-C3-C7环烷基甲基,其中所述-C3-C7环烷基或-C3-C7环烷基甲基任选地被卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至11元杂环所取代。
11.根据权利要求9所述的化合物,其中R3为H、环己基、环戊基、环丁基、环丙基、环己基甲基、环戊基甲基、环丁基甲基、环丙基甲基、苯基、苄基、吡咯烷-3-基、哌啶-4-基、(吡咯烷-3-基)甲基、(哌啶-4-基)甲基、其中所述环己基、环戊基、环丁基、环丙基、环己基甲基、环戊基甲基、环丁基甲基、环丙基甲基、苯基、苄基、吡咯烷-3-基、哌啶-4-基、(吡咯烷-3-基)甲基或(哌啶-4-基)甲基任选地被卤素、-OH、-CN、-COOR’、-OR’、-SR’、-OC(O)R’、-NHR’、-NR’R”、-CNR’R”、-NHC(O)R’、-NHC(O)NR’R”、-C(O)NR’R”、-NS(O)2R’、-S(O)2NR’R”、-S(O)2R’、胍基、硝基、亚硝基、-C1-C6烷基、芳基、-C3-C7环烷基或3至11元杂环所取代。
12.根据权利要求9所述的化合物,其中R3为环戊基或环己基。
13.根据权利要求1所述的化合物,其中Z2为未取代的苯基、吡啶或吡唑,或被卤素、-OR’、-Cl-C6烷基、-OR’OR”、-O(CH2)2NR’R”取代的苯基,其中所述-Cl-C6烷基任选地被一个或多个-OR’或NR’R”取代;R1为H、未取代的甲基或二甲胺;X为键;R2为H;R’或R”独立地为-H、甲基或乙基。
18.一种药物组合物,其包含根据权利要求1所述的化合物和药学上可接受的载体。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411908P | 2016-10-24 | 2016-10-24 | |
US62/411,908 | 2016-10-24 | ||
CN201780079730.7A CN110099906B (zh) | 2016-10-24 | 2017-10-24 | 作为激酶抑制剂的酰胺化合物 |
PCT/US2017/058071 WO2018081108A1 (en) | 2016-10-24 | 2017-10-24 | Amide compounds as kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780079730.7A Division CN110099906B (zh) | 2016-10-24 | 2017-10-24 | 作为激酶抑制剂的酰胺化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115160295A true CN115160295A (zh) | 2022-10-11 |
Family
ID=62023980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780079730.7A Active CN110099906B (zh) | 2016-10-24 | 2017-10-24 | 作为激酶抑制剂的酰胺化合物 |
CN202210797866.4A Pending CN115160295A (zh) | 2016-10-24 | 2017-10-24 | 作为激酶抑制剂的酰胺化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780079730.7A Active CN110099906B (zh) | 2016-10-24 | 2017-10-24 | 作为激酶抑制剂的酰胺化合物 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3532479B1 (zh) |
JP (1) | JP6948398B2 (zh) |
CN (2) | CN110099906B (zh) |
AU (1) | AU2017351216C1 (zh) |
CA (1) | CA3078347A1 (zh) |
IL (2) | IL266150B2 (zh) |
WO (1) | WO2018081108A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112367982A (zh) * | 2018-04-24 | 2021-02-12 | 转化药物开发有限责任公司 | 作为激酶抑制剂的酰胺化合物、组合物和治疗方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3782987A4 (en) * | 2018-04-18 | 2021-05-19 | Medshine Discovery Inc. | BENZOPYRAZOLE COMPOUND AS A RHO CINEMA INHIBITOR |
WO2019201296A1 (zh) * | 2018-04-18 | 2019-10-24 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的吡唑类化合物 |
WO2020142745A1 (en) * | 2019-01-04 | 2020-07-09 | Translational Drug Development, Llc | Methods of treating graft versus host disease and neoplastic disease with amide compounds |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical preparations that modulate IKZF2 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
US20110212969A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2012006203A1 (en) * | 2010-07-07 | 2012-01-12 | Boehringer Ingelheim International Gmbh | N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors |
WO2012006202A1 (en) * | 2010-07-07 | 2012-01-12 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
CN105358547A (zh) * | 2013-02-28 | 2016-02-24 | 百时美施贵宝公司 | 作为强效rock1和rock2抑制剂的苯基吡唑衍生物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
-
2017
- 2017-10-24 WO PCT/US2017/058071 patent/WO2018081108A1/en active Application Filing
- 2017-10-24 CN CN201780079730.7A patent/CN110099906B/zh active Active
- 2017-10-24 AU AU2017351216A patent/AU2017351216C1/en active Active
- 2017-10-24 IL IL266150A patent/IL266150B2/en unknown
- 2017-10-24 CN CN202210797866.4A patent/CN115160295A/zh active Pending
- 2017-10-24 EP EP17863621.3A patent/EP3532479B1/en active Active
- 2017-10-24 JP JP2019543185A patent/JP6948398B2/ja active Active
- 2017-10-24 CA CA3078347A patent/CA3078347A1/en active Pending
-
2023
- 2023-07-18 IL IL304547A patent/IL304547A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
US20110212969A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2012006203A1 (en) * | 2010-07-07 | 2012-01-12 | Boehringer Ingelheim International Gmbh | N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors |
WO2012006202A1 (en) * | 2010-07-07 | 2012-01-12 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US20120178752A1 (en) * | 2010-07-07 | 2012-07-12 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
CN105358547A (zh) * | 2013-02-28 | 2016-02-24 | 百时美施贵宝公司 | 作为强效rock1和rock2抑制剂的苯基吡唑衍生物 |
Non-Patent Citations (1)
Title |
---|
RAJAGOPALAN, LAKSHMAN E. ET AL: "Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity", 《JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》, vol. 333, no. 3, pages 707 - 716, XP055480499, DOI: 10.1124/jpet.110.166033 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112367982A (zh) * | 2018-04-24 | 2021-02-12 | 转化药物开发有限责任公司 | 作为激酶抑制剂的酰胺化合物、组合物和治疗方法 |
CN112367982B (zh) * | 2018-04-24 | 2024-05-07 | 转化药物开发有限责任公司 | 作为激酶抑制剂的酰胺化合物、组合物和治疗方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110099906B (zh) | 2022-07-26 |
AU2017351216B2 (en) | 2021-04-15 |
CN110099906A (zh) | 2019-08-06 |
AU2017351216A1 (en) | 2019-05-16 |
AU2017351216C1 (en) | 2021-10-14 |
WO2018081108A1 (en) | 2018-05-03 |
JP6948398B2 (ja) | 2021-10-13 |
IL266150B1 (en) | 2023-08-01 |
EP3532479A1 (en) | 2019-09-04 |
JP2019535812A (ja) | 2019-12-12 |
EP3532479B1 (en) | 2023-06-07 |
IL304547A (en) | 2023-09-01 |
CA3078347A1 (en) | 2018-05-03 |
IL266150A (en) | 2019-06-30 |
IL266150B2 (en) | 2023-12-01 |
EP3532479A4 (en) | 2020-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110099906B (zh) | 作为激酶抑制剂的酰胺化合物 | |
US10738007B2 (en) | Amide compounds as kinase inhibitors, compositions and methods of treatment | |
CN117105922A (zh) | 作为c-kit抑制剂的氨基噻唑化合物 | |
US11787803B2 (en) | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | |
CA2952692A1 (en) | Substituted imidazo[1,2b]pyridazine compounds | |
US20160221973A1 (en) | 3-aryl bicyclic [4,5,0] hydroxamic acids as hdac inhibitors | |
CN111032643B (zh) | 新的喹啉酮化合物 | |
TW202112784A (zh) | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 | |
EP3194407B1 (en) | Macrocyclic rip2 kinase inhibitors | |
CN112367982B (zh) | 作为激酶抑制剂的酰胺化合物、组合物和治疗方法 | |
JP7490569B2 (ja) | キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 | |
CA3202516A1 (en) | Aminothiazole compounds as c-kit inhibitors | |
AU2022206787C1 (en) | Amide compounds as kinase inhibitors, compositions and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40081274 Country of ref document: HK |